✦ LIBER ✦

Low-dose alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics

✍ Scribed by Khouri, I F; Albitar, M; Saliba, R M; Ippoliti, C; Ma, Y C; Keating, M J; Champlin, R E

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low incidence of acute graft-versus-host

✍ Byrne, J L; Stainer, C; Hyde, H; Miflin, G; Haynes, A P; Bessell, E M; Russell, 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 51 KB

Five Versus 2.5 mg/kg of Anti-Thymocyte-

✍ R. Devillier; R. Crocchiolo; L. Castagna; S. Fürst; J. El Cheikh; C. Faucher; T. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB

A high proportion of donor CD4+ T cells

✍ Yakoub-Agha, I; Saule, P; Depil, S; Micol, J-B; Grutzmacher, C; Boulanger-Villar 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 199 KB